RxDoctor Payments Data

Damien Mallat, MD

Gastroenterology · Dallas, TXNPI 1568421212

Payments from drug & device makers

$33,858in general payments, 2019–2025

Across 284 payments — averaging $119.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$24K
  • US Endoscopy$7K
  • Gilead$947
  • Braintree Laboratories, Inc.$877
  • Vivus LLC$390
  • Mauna Kea Technologies, Inc.$264
  • plus $924 from 14 others

What the payments were for

  • Consulting fees$6,75020%
  • Speaking & faculty fees$22,00065%
  • Food & beverage$4,19612%
  • Education$2271%
  • Gifts$6002%
  • Entertainment$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,858 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$157,777
Medicare patients
238
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase64$248,550
Humira(Cf) PenAdalimumab13$88,550
InflectraInfliximab-Dyyb14$55,897
LinzessLinaclotide91$54,099
ZenpepLipase/Protease/Amylase15$39,415
Dexlansoprazole DrDexlansoprazole17$4,647
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates81$4,199
SutabSod Sulf/Pot Chloride/Mag Sulf25$4,131
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl280$3,665
Rabeprazole Sodium105$2,281
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl109$1,662
Promethazine Hcl51$1,408
Ondansetron Hcl69$1,328
Omeprazole163$1,306
Sucralfate33$1,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$23,705$302,650155 claims
PfizerInflectra$193$55,89714 claims
Braintree Laboratories, Inc.Sutab$877$4,13125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →